Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33-CAR-T in R/R CD33-positive AML
NCT03126864Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD33-CAR-T cell infusion in acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Recommended Phase II Dose at 28 days. Started Aug 2017; status: terminated.
02
Drugs
CD33-CAR-T cell infusion
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03126864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126864.